Blinatumomab [BLI1]
The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in ADULT patients
- An application is being made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
- The patient is an adult. NB. There is a separate Blueteq form to be used for blinatumomab in this indication in children.
- The patient has relapsed or refractory Philadelphia negative acute lymphoblastic leukaemia (ALL).
- The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage therapy.
- Blinatumomab will only be requested by and administered in either bone marrow transplant centres or in major haematological centres that regularly treat patients with relapsed ALL and who have close and regular ALL multi- disciplinary team meetings and links with bone marrow transplant centres.
- The patient has an ECOG performance status of 0 - 2.
- A maximum of 5 cycles of treatment with blinatumomab will be administered.
- Blinatumomab in this indication is exempt from the NHS England Treatment Break policy.
- Blinatumomab will otherwise be used as set out in its Summary of Product Characteristics (SPC).
NHS funded From: 26 September 2017
Additional information
Current Form Version
Note
The data on this page was produced using version 1.363 of the CDF list, downloaded from an archive of NHS England’s website on 16 May 2025 at 14:00.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.